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Abstract: Precision medicine utilizing the genetic information of genes involved in the metabolism
and disposition of drugs can not only improve drug efficacy but also prevent or minimize adverse
events. Polypharmacy is common among multimorbid patients and is associated with increased
adverse events. One of the main objectives in health care is safe and efficacious drug therapy,
which is directly correlated to the individual response to treatment. Precision medicine can increase
drug safety in many scenarios, including polypharmacy. In this report, we share our experience
utilizing precision medicine over the past ten years. Based on our experience using pharmacogenetic
(PGx)-informed prescribing, we implemented a five-step precision medicine protocol (5SPM) that
includes the assessment of the biological–clinical characteristics of the patient, current and past
prescription history, and the patient’s PGx test results. To illustrate our approach, we present cases
highlighting the clinical relevance of precision medicine with a focus on patients with a complex
history and polypharmacy.
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1. Introduction
One of the main objectives in health care is a safe and efficacious pharmacological
intervention. However, drug response is highly variable and may depend on genetic variation, among other factors. The field of pharmacogenetics and genomics studies the impact
of genes and genetic variation on drug absorption, distribution, metabolism, excretion (also
referred to ADME), as well as the response of an individual (or lack thereof) to a given
drug or combination of drugs [1]. Thus, precision medicine should become the standard of
care, replacing “one size fits all” approaches when appropriate. Pharmacogenetic testing,
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ideally obtained before treatment initiation, can be a powerful tool to enhance patient care
and treatment outcomes [2].
Individual drug response is based on the pharmacokinetic and pharmacodynamic properties of the therapeutic agent(s), among others. Pharmacokinetics (PK) describes the processes
and fate of the drug, taking into account absorption, distribution, metabolism, and excretion.
In contrast, pharmacodynamics (PD) describes the biochemical and physiologic effects of the
body in response to a drug or drugs; drug response often includes drug receptors. Other
factors impacting PK and PD include compliance (taking the drug(s) as instructed), drug properties (formulation, pharmacologically active metabolites), and bioavailability (the fraction of
an administered dose of the drug that reaches the therapeutic target).
Among the most relevant pharmacogenes affecting PK are members of the cytochrome
P450 (CYP450) family. Enzymes encoded by the CYP1, CYP2, CYP3, and CYP4 families
are significant contributors to the Phase I biotransformation of drugs and xenobiotics [3–6];
more than 75% of drugs undergoing hepatic clearance are indeed metabolized by CYPs
of these families [7–9]. There is mounting evidence that genetic variation of CYP genes
contributes to lack of efficacy, drug interactions, and adverse events [9–12]. The diverse
combination of the different mechanisms and factors, such as genetic variation, influence the
activity of each CYP enzyme [13]. The major CYP isoforms responsible for the metabolism of
many drugs include CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and
CYP3A4/A5. CYP3A4 is the predominant isoform of the CYP family, usually responsible
for the metabolism of approximately 37% of drugs, followed by CYP2C9 (17%), CYP2D6
(15%), CYP2C19 (10%), CYP1A2 (9%), CYP2C8 (6%) and CYP2B6 (4%) [6,14] Although
CYP3A4 contributes to the metabolism of numerous drugs, genetic variation is not a
major contributing factor for highly variable activity [15]. In contrast, CYP2D6 is highly
polymorphic with over 140 different star alleles variants described to date (cataloged by
the Pharmacogene Variation Consortium, available online: https://www.pharmvar.org/
(accessed on 26 January 2020)) [16–18], causing a wide range of activity [19]. Although
the Clinical Pharmacogenetics Consortium (CPIC) published recommendations for the
translation of genotype phenotype is not standardized across clinical laboratories [19]. It is
necessary to take into account that the pharmacogenetic variations are different in regard
to the different populations around the world [20].
Therefore, determining a patient’s metabolic profile for one or multiple ADME genes can
guide drug selection and dose to avoid adverse events related to the drug’s metabolism [21,22].
Phase II enzymes such as UGTs and drug transporters such as ABCB1 (MDR1) also
contribute to drug metabolism and response [23]. Another transporter of importance
is SLCO1B1, which is associated with plasma concentrations of certain statins (HMGCoA reductase inhibitors), increasingly prescribed to decrease the risk of cardiovascular
diseases [24].
With aging populations, worldwide polypharmacy is becoming the rule rather than
the exception for the elderly and comorbid adult patients. Concerns about polypharmacy
include adverse events due to drug–drug interactions and pose a financial burden on health
systems. It has been shown that both increase with the number of drugs prescribed for a
patient [25–27].
Taking all relevant patient information into account, including PGx test results, will
allow the clinician to tailor drug therapy, i.e., the choice of drug(s) and dose, for each patient,
and practice what is commonly referred to as precision medicine. We have developed a
5-step precision medicine (5SPM) polypharmacy protocol and applied this approach in
clinical practice. In this report, we summarize our ten-year experience utilizing PGx testing
and practicing precision medicine.
2. Materials and Methods
2.1. Subjects and Study Design
All patients who underwent testing in the Pharmacogenetic Unit of the University
Hospital of Salamanca over 10 years (2007 to 2016) were included, regardless of their
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origin. All methods were carried out following relevant guidelines and regulations. Written
informed consent was obtained from all patients according to the recommendations of the
Ethical Committee of the University Hospital of Salamanca. This committee approved the
study with the Ref Cod. CEIm PI 2020 12 642.
Study patients were classified into two groups:

•
•

Monotherapy: a patient’s PGx test was requested for a specific gene.
Polytherapy: patients on polypharmacy. A model designed to analyze polymedicated
patients, called 5SPM, was applied to this patient group.

2.2. 5-Step Precision Medicine Model
2.2.1. Step 1: Clinical, Epidemiological and Therapeutic Data Collection
Data collection included each patient’s medical condition(s), current prescriptions (classified by the anatomical, therapeutic, chemical (ATC) classification system), and therapeutic
response. The number of prescribed drugs ranged from 2 to 18 for the polytherapy group.
The reason for referral to the precision medical unit for PGx testing (e.g., adverse effects,
therapeutic failure) was recorded, as well as patient age, gender, and medication history.
Drugs were classified using the ATC system according to the organ or system on which
they act and their therapeutic, pharmacological, and chemical properties per the World
Health Organization Collaborating Centre for Drug Statistics Methodology (WHOCC) [28].
2.2.2. Step 2: Predictions of Drug–Drug Interactions and Pharmacokinetic
Specific Pathways
Publicly available resources, including the Pharmacogenomic Knowledgebase (PharmGKB) [29] PubMed-NCBI [30], SuperCYP [31], and the Pharmacogene Variation (PharmVar) Consortium [16,32], were used to analyze drug–gene and drug–drug interaction of the
specific drugs prescribed to each patient.
2.2.3. Step 3: Pharmacogenetic Analysis of Selected Genes
PGx testing was performed in probe-based assays using the LightCycler platform
(Roche Diagnostics), the AmpliChip CYP450 Test (Roche Molecular Diagnostics, Pleasanton,
CA, USA) [33], and the Autogenomics platform (Carlsbad, CA, USA) [34]. As previously
reported [35], PGx laboratory testing was performed following the directives of the European Molecular Genetics Management Network. Quality norms were applied following
the UNE-EN-ISO 15189 Normative in the Accredited Section of Molecular Genetics and
Pharmacogenetics laboratory of the University Hospital in Salamanca. The normative
included preanalytical, analytical and post-analytical control, qualification of personal, and
internal and external validity.
Selected CYP2D6 no-call results were further characterized in the Division of Clinical
Pharmacology, Toxicology & Therapeutic Innovation laboratory at Children’s Mercy Kansas
City using a combination of approaches including long-range (XL) PCR, Sanger sequencing
and quantitative copy number analysis [36–38].
Genotype was translated into phenotype per the CYP2D6 Diplotype-Phenotype Table available through PharmGKB (available online: https://www.pharmgkb.org/page/
pgxGeneRef (accessed on 3 June 2018)).
2.2.4. Step 4: Rationalized PGx-Guided Adjustments of Drug Therapy
The drugs prescribed and their dose were revised or changed based on a patient’s
predicted phenotype and the potential drug–drug interactions of the drugs prescribed.
The objectives were to identify which drugs were not efficiently metabolized, which drugs
were mainly metabolized by the same enzyme, and which drugs were inhibitors causing
the patient to have phenotype different from that predicted by genotype (also known as
phenocopy) with the goal to decrease potential harmful drug interactions. The patient’s
prescription was modified accordingly.
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2.2.5. Step 5: Assessment of the Intervention and Model Reevaluation
The model was continuously evaluated by analyzing patient outcome based on the
changes made following PGx testing. Clinicians followed the outcome of each patient and
provided feedback regarding the intervention.
2.3. Statistical Analysis
Descriptive statistics was used to determine central tendency and dispersion. The
normality of the distribution was assessed using the Kolmogorov–Smirnov test. Bivariate
analysis for qualitative variables was carried out by χ2, Fisher exact test, and Montecarlo
test. Bivariate analysis for quantitative and qualitative variables was carried out by ANOVA.
The equality of variances was ensured using the Levene test. All statistical analyses were
performed using SPSS version 17.0 (Chicago, IL, USA).
3. Results
A total of 1540 patients were studied in the Pharmacogenetics and Precision Medicine
Unit of the University Hospital of Salamanca. A total of 1340 patients were referred
to the unit to analyze the response to a specific drug, however, as shown in Table 1,
only 210 patients were qualified for the 5SPM model due to experiencing adverse effects,
intolerance to treatment, partial response, or therapeutic failure in a polypharmacy regimen,
as we can observe in Table 1.
Table 1. Demographics and medication request.
Variable

Value

PATIENTS
Total number of caucasian patients included:
210
- Average age (range; years)
48 (9–91)
- Male: Female (%)
50.5: 49.5
PHARMACOGENETIC ANALYSIS REQUEST
Application request (% of total)
- Adverse events
47.1
- Poor response to treatment
19.0
- Others
33.9
Medical specialties applicants (% of total)
- Psychiatry
- Eating disorders unit
65.2
- Allergy
9.5
- Others (rheumatology, pediatric, oncology, neurology,
4.7
pharmacy, hematology, infectious disease)
20.6

Table 1 and Supplementary Figures S1 and S2 summarizes patient demographics, as
well as the reasons for genetic analysis and clinical services. Figure 1 includes selected
data of the analyzed drugs and the classification of these medications according to the ATC
nomenclature, highlighting more than 60% of the central nervous system group.
3.1. Clinical Data Collection
Half of the patients were female (49.5%). The mean age is 43.9 ± 18.1 vs. 47.1 ± 18.8
in males. Supplementary Figure S3 shows a box plot with the age distribution. No
statistically significant differences were observed between both groups according to age
(Fisher’s p-value = 0.21). Fifteen % of the patients were older than 65 years of age. Of the
enrolled patients, 92.5% had neuropsychiatric disorders, mainly psychosis, depression, and
bipolar disorders representing 66.74% of the medications, followed by patients treated for
cardiovascular conditions (22.5% of patients representing 9.8% of the medications).
Only in 1% of cases was PGx analysis performed before the initial prescription. Nearly
half of the patients (47.1%) were referred to the unit for adverse events or intolerance,
and 19.0% were referred owing to partial response or therapeutic failure. Therapeutic
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failure was observed more often in men and adverse events in women, although these
observations were not statistically significant (Fisher’s p-value = 0.26).

Figure1.1.Medication-use
Medication-usedata:
data:(a)
(a)number
numberofofmedications
medicationsper
perpatient
patient(mean);
(mean);(b)
(b)type
typeofofmedication.
medication.
Figure

most often complained that the drug did not help (83.9%), con3.1. Psychiatric
Clinical Datapatients
Collection
trasting patients seen in the allergy department, which reports that 75% had adverse events
Half of the patients were female (49.5%). The mean age is 43.9 ± 18.1 vs. 47.1 ± 18.8 in
(Fisher’s p-value < 0.001).
males. Supplementary Figure S3 shows a box plot with the age distribution. No statistically significant differences were observed between both groups according to age (Fisher’s
p-value = 0.21). Fifteen % of the patients were older than 65 years of age. Of the enrolled
patients, 92.5% had neuropsychiatric disorders, mainly psychosis, depression, and bipolar
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3.2. Pharmacological Interactions
A total of 956 prescriptions were recorded for these patients, with a mean of 5 drugs
per patient (range 1 to 18 drugs); 45% of the patients had prescriptions for 5 or more
drugs. Potential drug–gene (Table 2) and drug–drug (Table 3) interactions were analyzed.
For drug–gene interactions, patients predicted to have poor, intermediate, or ultrarapid
phenotypes were selected, and may therefore have a higher risk to present with toxicity
or treatment failure due to drug–gene interaction(s). A total of 728 potential drug–gene
interactions were identified. From these interactions, we selected 25 medications which
were most commonly prescribed (Table 2), and 24 of them had the highest number of
interactions (Table 3). For the analysis of drug–drug interactions, route of metabolism
(same or different routes) and whether they act as inhibitors, substrates or inducers was
taken into account. A total of 2030 possible drug-drug interactions were determined.
Supplementary Figure S4 summarizes the top 10 drug–gene and drug–drug interactions.
Table 2. Top 25 medications involved in potential drug–gene interactions in study population.
Rank

Drug

Drug-Gene Interaction Counts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Omeprazole
Quetiapine
Olanzapine
Risperidone
Venlafaxine
Aripiprazole
Sertraline
Valproic Acid
Paracetamol/Acetaminophen
Clonazepam
Haloperidol
Clozapine
Fluoxetine
Alprazolam
Escitalopram
Methadone
Zolpidem
Atorvastatin
Diazepam
Cholecalciferol
Trazodone
Carbamazepine
Paroxetine
Rosuvastatin
Bupropion

53
47
42
37
34
33
33
24
24
20
20
19
18
15
15
15
15
13
11
9
9
8
8
8
7

Finally, as shown in Figure 2, drug–gene interactions were compared with drug–drug
interactions for each CYP isoenzyme. This allowed us to determine the percentage of
drug–drug interactions that could be avoided according to genotype. For CYP3A4, the
majority of individuals had genotypes predicting normal metabolism. However, for other
enzymes such as CYP3A5 or CYP2C19, genotype played a considerably more significant
role suggesting that the inclusion of genotype information could avoid a high percentage
of interactions (Fisher’s p-value < 0.001).
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Table 3. Top 24 medications involved in potential drug–drug interactions in study population.
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Rank

Drug

Drug-Drug Interaction Counts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Omeprazole
Olanzapine
Quetiapine
Sertraline
Valproic Acid
Aripiprazole
Venlafaxine
Clozapine
Risperidone
Fluoxetine
Paracetamol/Acetaminophen
Clonazepam
Escitalopram
Methadone
Zolpidem
Haloperidol
Mirtazapine
Diazepam
Trazodone
Atorvastatin
Bupropion
Simvastatin
Cholecalciferol
Paroxetine

141
138
113
100
83
80
70
68
65
62
59
59
38
35
35
32
31
27
27
25
24
24
23
19

8 of 14

Figure2.2.Potential
Potentialdrug–gene
drug–geneand
anddrug–drug
drug–druginteractions
interactionscounts
countsininthe
thestudy
studypopulation.
population.
Figure

3.3. Pharmacogenetic Analysis
A total of 210 patients were genotyped for genetic variants, including 10,400 alleles
corresponding to CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and
ABCB1 as detailed in in Table 4.
Table 4. Summary of variants tested

Gene

Variants (SNPs)
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3.3. Pharmacogenetic Analysis
A total of 210 patients were genotyped for genetic variants, including 10,400 alleles
corresponding to CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and
ABCB1 as detailed in in Table 4.
Table 4. Summary of variants tested.
Gene

Variants (SNPs)
rs1799853 (CYP2C9*2)

CYP2C9

rs1057910 (CYP2C9*3)
rs4244285 (CYP2C19*2)

CYP2C19

rs4986893 (CYP2C19*3)
rs12248560 (CYP2C19*17)

CYP3A4

rs2740574 (CYP3A4*1b)

CYP3A5

rs776746 (CYP3A5*3)

ABCB1

rs1045642 (C3435T)
rs1080985 (CYP2D6*2A)
rs1065852 (CYP2D6*10 and *4)
rs28371706 (CYP2D6*17, *40, *58 and *64)
rs5030655 (CYP2D6*6)
rs5030865 (CYP2D6*8 and *14)
rs3892097 (CYP2D6*4)

CYP2D6

rs5030862 (CYP2D6*12)
rs61736512 (CYP2D6*1, *1xN, *2xN, *3xN, *4xN, *6xN,
*9x2, *10x2, *17x2, *29, *29x2, *35xN, *36xN, *41x2,
*43xN, *45xN, *70, *107 and *149)
rs28371725 (CYP2D6*41)
rs35742686 (CYP2D6*3)
rs5030656 (CYP2D6*9)
rs16947 (CYP2D6*2)
rs5030867 (CYP2D6*7)

CYP2B6

rs3745274 (CYP2B6*6)

CYP1A2

rs762551 (CYP1A2*1F)

Figure 3 summarizes the genotype and phenotype information of the patients. We like
to highlight that PGx testing and analysis were performed individually, i.e., in a personalized manner for each patient based on their genotype and drug treatment. Concerning
ABCB1, up to 66% of patients carried at least one T allele that has been associated with
decreased transporter function.
Significant differences were observed regarding the phenotype and the indication of
the study. For instance, 39.4% of patients who were intermediate metabolizers for CYP2C9,
Fisher’s p-value = 0.020, were included in the study due to adverse event reports vs. 16.7%
due to intolerance to treatment.
Regarding CYP2D6, the most common phenotype was normal metabolizers (86.9%).
On the other side, allele frequencies associated with intermediate and poor metabolism
were 0.35.
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this duplication is less frequent in Salamanca than in other regions worldwide. [37]. Furthermore, one patient revealed a complex genotype, CYP2D6*68 + *4/*77 + *2 with tandem
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3.4. Identification of Novel Allelic Variants
Some patients had no-calls when genotype was tested on the Roche AmpliChip.
Further characterization of selected cases by Sanger sequencing revealed three CYP2D6
haplotypes, which were not recognized by the AmpliChip software. Among them were
theno function CYP2D6*31 allele [36], and the CYP2D6*9x2 gene duplication [37]. Interestingly, this duplication is less frequent in Salamanca than in other regions worldwide. [37].
Furthermore, one patient revealed a complex genotype, CYP2D6*68 + *4/*77 + *2 with
tandem arrangements and hybrid genes on both alleles which likely interfered with the
AmpliChip test [38].
3.5. Clinical Results
The integration of PGx into practice allowed us to gain valuable information regarding
the therapeutic management of patients. An example of the clinical application of the
model has previously been described by Isidoro et al. [39].
Psychiatric Patients
To demonstrate our approach, we present here the results for psychiatric patients.
These were as follows: 40% of psychiatric patients had genotypes predicting altered enzymatic activity that could impact pharmacologic response. Specifically, 92% of patients had
gene variants affecting the metabolism of CYP2D6 substrates. Among bipolar patients, all
having a poor metabolizer phenotype showed maniac switching when CYP2D6 substrates,
such as selective serotonin reuptake inhibitors, were prescribed [37].
Among patients with eating disorders, 64% of anorexic patients suffered from adverse
events; each of these patients had a genotype that affected the metabolism of some of the
prescribed medications and clinical symptoms improved for 93.8% of the patients (i.e.,
gained weight) after undergoing the application of precision medicine.
3.6. Economic Implications
Considerable cost reductions were observed after the application of PGx testing in our
patients. For example, for a representative group of patients with infectious diseases, up
to €8182 were saved for each patient with CMV treated with interferon, or €43,549/year
for HIV patients treated with efavirenz [40] by genotyping IL28 or CYP2B6, respectively.
Applying a theoretical model allowed us to infer up to €587/patient of avoided hospital
costs [26]. This model was developed in 2014 in the University Hospital of Salamanca and
allowed us to infer considerable cost reductions if the PGx testing took place before the
outcoming of adverse effects. It also took into account the quality of the age expectancy [26].
An economic impact of the model in psychotic patients has been previously reported [41]. In this study, we achieved a reduction in direct costs, including both hospitalization and pharmacotherapy, as well as a reduction in total costs in 67% of patients
who underwent the application of this pharmacogenetic approach.
In addition, PGx testing of a gene panel was up to €500 and results were useful to
inform current therapy and have the potential to guide future medication needs. Thus, PGx
testing is cost-effective over a patient’s lifetime.
4. Discussion
Polypharmacy is unavoidable for many patients, especially the elderly or those suffering from complex diseases or conditions. It has been shown that the more physicians
are involved in treating a patient, the higher the risk of adverse events [39]. In addition,
patients with an unfavorable pharmacological response tend to be treated with increasing
doses or numbers of drugs, which negatively impacts the patient and adds to increased
costs. Concerns about polypharmacy include adverse events, interactions, and costs, that
increase with the number of drugs. Taken together, this points to an urgent need for personal medicine models that consider drug interactions. As demonstrated by our model, the
integration of PGx and careful evaluation of drug–drug and drug–gene interactions has the
potential of benefitting a large number of patients.
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As polypharmacy increases with age, there is an additional risk of experiencing
adverse events to pharmacological drugs after age 65 [26]. However, in our study cohort,
only 15% of the patients with polypharmacy were older than 65, strongly suggesting that
this is not solely an age-related problem but also affects many younger patients.
In this investigation, most patients were studied after receiving a prescription, which
had the advantage of assessing relationships with the clinical response. Thus, potential risk
could not be avoided a priori. Interestingly, the indication of the pharmacogenetic study in
Psychiatry was significantly different compared to that in Allergy, this may be due to the
high number of patients with drug reactions in this later speciality.
We also observed a correlation between CYP2C9 PGx test results and reasons for
referral. Specifically, the majority of patients with genotypes predicting intermediate
metabolizer status were included due to adverse events.
This study also demonstrates the limitations of genotyping platforms and the necessity to follow-up on no-call results. No-calls often imply the presence of rare or novel
SNPs or haplotypes. Adding newly discovered variants and haplotypes into databases
such as PharmVar will enhance research and ultimately improve test platforms and test
interpretation. In addition, we also provide examples of cost savings and emphasize that
PGx information is saving costs at the time it is requested and has the potential to lower
costs long term.
The majority of patients were referred from psychiatry which we attribute, at least
in part, to the previous experience of physicians in this area [42,43]. Polypharmacy in
psychiatric patients is common, and variability in drug response is routinely being observed [35,44]. Therefore, it was not surprising that nearly all patients with variants
affecting CYP2D6 metabolic capacity were taking at least one drug metabolized by this enzyme. Since numerous clinically used drugs are metabolized by CYP2D6 (20% or more [45])
and given the wide range of interindividual variability [39,46], our findings corroborate
the importance of CYP2D6 genotype and its contribution to adverse events in psychiatric
patients. Although most patients were normal metabolizers, about 13% were poor, intermediate, or ultrarapid metabolizers and, thus, at risk of problems with the medication
prescribed. We would also like to highlight patients with eating disorders, particularly
those poor metabolizers that all improved after PGx testing and intervention based on their
test results.
5. Conclusions
Although the integration of PGx into precision medicine continues to grow, many
challenges remain. One challenge is integrating PGx information with all other data
to improve drug therapy while saving costs. To address this, we have developed and
applied a PGx model, 5SPM, which demonstrates the utility of PGx. Experience of over
ten years supports the approach of individualized drug therapy, especially in the setting
of polypharmacy.
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